Use of high flux SCFA-derivatized monosaccharides in recombinant glycoprotein production
Methods of glycoprotein production employing monosaccharides capable of producing a global increase in flux through the sialic acid pathway are provided.
1. A method for producing a glycoprotein possessing increased half-life, reduced toxicity and/or altered immunogenicity comprising: contacting a protein under conditions that allow glycoprotein formation to occur with a compound selected from the group consisting of the following compounds:
wherein R is selected from the group consisting of
2. The method of claim 1 , wherein said glycoprotein is selected from the group consisting of an antibody, an enzyme and a hormone.
3. The method of claim 2 , wherein said glycoprotein is an antibody component of intravenous immunoglobulin (IVIG) therapy.
4. The method of claim 2 , wherein said glycoprotein is butyl-cholinesterase enzyme.
5. The method of claim 2 , wherein said glycoprotein is human growth hormone (HMI).
6. The method of claim 1 , wherein said glycoprotein is produced in a mammalian cell.
7. The method of claim 6 , wherein said mammalian cell is a Chinese hamster ovary (CHO) cell.
8. The method of claim 1 , wherein said glycoprotein possesses increased sialylation as compared to a control glycoprotein not contacted with said compound.